EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening

Laura N. Venditti, Tara A. Lavelle, Charles P. Venditti

Genetics in Medicine Open · 2026-11 · 104523

DOI: 10.1016/j.gimo.2026.104523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetics in Medicine Open, 2026-11. Verfasst von Laura N. Venditti und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Human Genome Research Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • National Human Genome Research Institute

Zitieren

APA

Venditti, L. N., Lavelle, T. A., & Venditti, C. P. (2026). Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening. Genetics in Medicine Open, 104523. https://doi.org/10.1016/j.gimo.2026.104523

Vancouver

Venditti LN, Lavelle TA, Venditti CP. Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening. Genetics in Medicine Open. 2026:104523. doi:10.1016/j.gimo.2026.104523

BibTeX
@article{Venditti2026,
  author = {Venditti, Laura N. and Lavelle, Tara A. and Venditti, Charles P.},
  title = {Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening},
  journal = {Genetics in Medicine Open},
  year = {2026},
  pages = {104523},
  doi = {10.1016/j.gimo.2026.104523}
}
Kostenlos starten →